IL-6: regulator of Treg/Th17 balance (Q37768101)

22 August 2017

1 reference

title

IL-6: regulator of Treg/Th17 balance (English)

1 reference

22 August 2017

Akihiro Kimura

1

1 reference

PubMed ID

20583029

22 August 2017

Tadamitsu Kishimoto

series ordinal

2

1 reference

PubMed ID

20583029

22 August 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

European Journal of Immunology

22 August 2017

1 reference

22 August 2017

40

1 reference

22 August 2017

1830-1835

1 reference

22 August 2017

7

1 reference

Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages

22 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Basophils produce IL-4 and accumulate in tissues after infection with a Th2-inducing parasite

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Helper T cells regulate type-2 innate immunity in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

A functional dichotomy in CD4+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Interleukin-17 family members and inflammation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Regulatory T cells exert checks and balances on self tolerance and autoimmunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Transforming growth factor-beta induces development of the T(H)17 lineage

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-beta 2) regulates beta-fibrinogen and albumin mRNA levels in Fao-9 cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Impaired immune and acute-phase responses in interleukin-6-deficient mice.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Molecular cloning and expression of an IL-6 signal transducer, gp130

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Interleukin-6 and its receptor: a paradigm for cytokines

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Jaks and Stats in signaling by the cytokine receptor superfamily

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Interleukin-17 family and IL-17 receptors

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Increased expression of interleukin 17 in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

In-vitro-induced Th17 cells fail to induce inflammation in vivo and show an impaired migration into inflamed sites.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Stat3 and Stat4 direct development of IL-17-secreting Th cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Cutting edge: IFN-gamma regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Regulatory T cells and mechanisms of immune system control

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

https://api.crossref.org/works/10.1002%2FEJI.201040391

1 reference

7 January 2021

Interleukin-10-secreting type 1 regulatory T cells in rodents and humans.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Interleukin-6: discovery of a pleiotropic cytokine

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201040391

7 January 2021

Identifiers

DOI

10.1002/EJI.201040391

1 reference

22 August 2017

1 reference

PubMed ID

20583029